Canadian Agency Recommends Ruzurgi Be Reimbursed with Conditions

Canadian Agency Recommends Ruzurgi Be Reimbursed with Conditions

293536

Canadian Agency Recommends Ruzurgi Be Reimbursed with Conditions

The Canadian Agency for Drugs and Technologies in Health (CADTH) has recommended that Ruzurgi (amifampridine) be reimbursed for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in individuals 6 and older, but only if certain conditions are met. These include patients for whom the medication has been prescribed by a neurologist with experience caring for LEMS patients, and if Ruzurgi’s cost is reduced to a level that would be more acceptable to public payers. It is…

You must be logged in to read/download the full post.